Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
NCT ID: NCT01202279
Last Updated: 2020-12-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1179 participants
INTERVENTIONAL
2009-10-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mucinex D
Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
Guaifenesin
1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Placebo
Placebo given bid with a full glass of water for 7 days
Placebo
Placebo bid for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Guaifenesin
1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Placebo
Placebo bid for 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Reckitt Benckiser Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Advantage, Inc.
Mesa, Arizona, United States
Med Center
Carmichael, California, United States
Research Center of Fresno, 3636 N. First Street, Suite 141
Fresno, California, United States
Coastal Medical Research Group, Inc., 47 Santa Rosa Street
San Luis Obispo, California, United States
Coastal Connecticut Research, LLC, 342 Montauk Avenue
New London, Connecticut, United States
Glasgow Family Practice
Newark, Delaware, United States
Koch Family Medicine, 81A E. Queenwood Road
Morton, Illinois, United States
Sterling Research Group, Ltd., 650 Sprucewood Lane
Erlanger, Kentucky, United States
Clinical Associates Research, 750 Main Street, Suite 310
Reisterstown, Maryland, United States
Park Place Family Practice & Internal Medicine
Taylor, Michigan, United States
Immedicenter
Bloomfield, New Jersey, United States
Peters Medical Research
High Point, North Carolina, United States
(Piedmont Medical Research Assoc., Inc. d/b/a), Crescent Medical Research
Salisbury, North Carolina, United States
Parsons Avenue Medical Clinic
Columbus, Ohio, United States
Legacy Clinical Research, LLC, 1204 W. Willow Road, Suite B
Enid, Oklahoma, United States
Integrated Medical Research, PC
Ashland, Oregon, United States
Harleysville Medical Associates, 176 Main Street
Harleysville, Pennsylvania, United States
Kastelic MD & Associates, 322 Warren Street, Suite 300
Johnstown, Pennsylvania, United States
Durham Physicians, P.C.
Penndel, Pennsylvania, United States
Palmetto Medical Research, 180 Wingo Way, Suite 203
Mt. Pleasant, South Carolina, United States
TriCities Medical Research
Bristol, Tennessee, United States
Village Health Partners
Plano, Texas, United States
Independence Family Medicine, 813 Independence Blvd., Suite A
Virginia Beach, Virginia, United States
Amherst Family Practice, 1867 Amherst Street
Winchester, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Septimus EJ, Albrecht HH, Solomon G, Shea T, Guenin EP. Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study. Curr Ther Res Clin Exp. 2017 Apr 28;84:54-61. doi: 10.1016/j.curtheres.2017.04.004. eCollection 2017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-MUCD-001
Identifier Type: -
Identifier Source: org_study_id